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Introduction: Methotrexate (MTX) has been for decades a standard treatment in a wide range of conditions, from
malignancies to rheumatoid arthritis (RA). Despite this long experience, the mechanisms of action of MTX remain
incompletely understood. Reported immunologic effects of MTX include induction of increased production of some
cytokines, an effect that seems to be at odds with the generally anti-inflammatory effects of this drug in diseases
like RA. To further elucidate these immune activities, we examined effects of MTX on the human monocytic cell line
U937.
Methods: The U937 cell line was treated in vitro with pharmacologic-range concentrations of MTX and effects on
production of interleukin (IL)-1, IL-6 and TNF alpha were measured. Changes in gene expression for IL-1 and IL-6
and specificities in the Jun-N-terminal kinase (JNK) signaling pathway including JNK 1, JNK2, JUN and FOS were also
determined. The contribution of NF-kB, folate and adenosine pathways to the observed effects was determined by
adding appropriate inhibitors to the MTX cultures.
Results: MTX mediated a dose-dependent increase in IL-1 and IL-6 in U937 cells, as measured by secreted proteins
and levels of gene expression. The increased cytokine expression was inhibited by addition of parthenolide and
folinic acid, but not by caffeine and theophylline, suggesting that NF-kB and folates, but not adenosine, were
involved in mediating the observed effects. When U937 cells were cultured with MTX, upregulated expression of
JUN and FOS, but not JNK 1 or 2, also was observed.
Conclusions: MTX induces expression of proinflammatory cytokines in U937 monocytic cells. These effects might
mediate the known toxicities of MTX including pneumonitis, mucositis and decreased bone mineral density.Introduction
Methotrexate (MTX) was first introduced into clinical
practice as a chemotherapeutic agent more than six de-
cades ago and the continued use of this older drug is evi-
dence of its remarkable therapeutic effects [1-3]. Treatment
with MTX is a key reason for the transformation of acute
childhood leukemias from being uniformly fatal to having
long-term survival rates of 70% or more. In rheumatoid
arthritis (RA), MTX is considered a cornerstone of all ther-
apies and its use is largely responsible for improved func-
tional and structural outcomes in these patients [4]. Even
the newer biologic agents in RA are generally given in com-
bination with MTX to maximize therapeutic effects [5]. At
the same time, the adverse events profile of MTX requires* Correspondence: nolsen@hmc.psu.edu
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stated.application of caution in its use. Pulmonary toxicity with
MTX is a rare but potentially fatal disorder and decreases
in bone density may be another long-term consequence of
treatment, especially at higher doses used in chemothera-
peutic regimens [6].
The mechanisms of action of MTX are related at least
in part to antiproliferative effects that are dependent on
inhibition of dihydrofolate reductase and inhibition of
nucleotide synthesis pathways [7]. Other activities, includ-
ing release of adenosine and inhibition of polyamines, are
thought to contribute to the anti-inflammatory effects [8].
Some actions of MTX also depend on stimulation of the
production of reactive oxygen species (ROS) and induc-
tion of T lymphocyte apoptosis [9]. In previous studies, we
have shown that MTX treatment of patients with RA re-
stores toward normal expressed levels of genes and associ-
ated proteins related to cell cycle checkpoint pathways
[10], and more recent studies suggest that expressed levelstd. This is an Open Access article distributed under the terms of the Creative
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in vivo by MTX [11].
The many documented effects of MTX include stimula-
tion of both pro- and anti-inflammatory pathways. In some
situations, such as pneumonitis and mucositis, enhanced
cytokine production has been postulated to contribute to
tissue damage [12-14]. The loss of bone density seen after
long-term treatment with MTX, which is a greater concern
in chemotherapeutic than in anti-inflammatory regimens,
also has been attributed to increased levels of cytokines
and activation of nuclear factor kappa B (NF-kB) [15].
Our previous studies with MTX have been focused on ef-
fects in T lymphocytes, and have shown that these cells are
primed by MTX for apoptosis by a JNK-dependent mech-
anism [10,16]. The objective of the present study was to
examine effects of MTX on cells of monocyte lineage, util-
izing the human line U937. Comparisons were made with
another drug used for RA, hydroxychloroquine (HCQ),
which acts through lysosomes including those in macro-
phages [17]. The findings of the present investigation show
that MTX enhances production of the inflammatory medi-
ators IL-6 and IL-1. Whether this action of MTX contrib-




Methotrexate (MTX), hydroxychloroquine (HCQ), lipo-
polysaccharide (LPS), caffeine (CAFF), theophylline (THEO),
folinic acid (FA) and parthenolide (PAR) were from Sigma-
Aldrich (St Louis, MO, USA). Secreted interleukin (IL)-
1beta, IL-6 and tumor necrosis factor (TNF)-alpha in
culture supernatants were quantitated using enzyme-
linked immunosorbent assay (ELISA) kits from Abcam
(Cambridge, MA, USA) and results were expressed in
standardized concentrations using reagents provided
with these kits.
Cell preparation and culture
The human cell lines U937 (monocytes) and Jurkat (T
lymphocytes) were obtained from ATCC (Manassas, VA,
USA) and were maintained in suspension culture with
RPMI 1640 supplemented with 10% fetal calf serum
(FCS). Cell viability was determined by trypan blue dye ex-
clusion and by the Vybrant MTT Cell Proliferation Assay
(Invitrogen, Carlsbad, CA, USA). MTT is 3-(4,5-dimethyl-
thiazol-2-yl)-2,5 diphenyl tetrazolium bromide and is used
to quantify numbers of cells in culture [18]. Concentra-
tions of MTX, HCQ, LPS and PAR ranged from 0.01 uM
to 1 uM, as indicated in individual experiments. Of note,
the concentration of MTX achievable after oral ingestion
of a 20 mg tablet yields a plasma concentration of 0.1 uM
after 10 hours [10]. Cultures were incubated in a humi-
dified atmosphere with 5% CO2 for 24 to 72 hours, asindicated in specific experiments. These studies were car-
ried out in a human cell line and no institutional ethics
approval or patient consent was required.
Quantitative RT-PCR
Total RNA was purified from cell pellets using the Qiagen
RNeasy Mini Kit (Germantown, MD, USA) and quanti-
tated with a NanoDrop 2000 (Thermo Scientific, Wilming-
ton, DE, USA). Preparation of cDNA was done using the
High Capacity RNA-to-cDNA Kit (Applied Biosystems/
Life Technologies, Carlsbad, CA, USA) with 100 to 200 ng
RNA per synthesis reaction. RT-PCR analysis was per-
formed for selected genes using TaqMan Gene Expression
Assays (Life Technologies) with GAPDH as the house-
keeping control gene with an ABI-7300 Real Time PCR in-
strument. Expression values are normalized to GAPDH
levels using the following formula: 2(GAPDH Ct-Test gene CT).
Flow cytometry
Cells were suspended at 1 × 106/ml in phosphate-buffered
saline with 2% bovine serum albumin (BSA) and 0.1%
sodium azide and surface stained with PE-Cy-7-labeled
anti-CD14 (Becton Dickinson, Franklin Lakes, NJ, USA).
Apoptosis was quantitated using the PE Annexin V Apop-
tosis Detection Kit (BD Pharmingen, BD Biosciences).
This kit utilizes double-staining with PE Annexin V and
7-amino actinomycin D (7-AAD) to distinguish between
viable cells and those that are undergoing apoptosis. Stain-
ing data were collected in a BD FACSCanto II in the
Hershey Medical Center Flow Cytometry Core and FlowJo
Software (Tree Star, Inc., Ashland, OR, USA) was used to
analyze the results.
Statistics
Data were expressed as mean and standard deviation of
the mean. The significance between the two experimen-
tal groups was determined by Student’s t test or, for
comparison of three or more groups, by a one-way ana-
lysis of variance (ANOVA) with Tukey’s or Dunnett’s
multiple comparisons tests used as post tests where indi-
cated. The analyses and the graphics were done with
Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA).
P values of less than 0.05 were considered significant.
Results
Cell viability and apoptosis
We have shown previously that MTX primes Jurkat T cells
for increased sensitivity to apoptosis and low levels of
apoptosis are induced in these cells by MTX itself [10].
Compared to Jurkat T cells, U937 cells had reduced via-
bility in vitro as measured by trypan blue dye exclusion
(Figure 1). After 72 hours in culture, this difference was
observed for cultures even with no added agents (92% vs.
96%; P = 0.001), with 1 uM MTX (63% vs. 87%; P = 0.0004)






























































































Figure 1 U937 and JKT cell lines were cultured with or without MTX (1 uM) and LPS (25 ug/ml). Viability determined by trypan blue dye
exclusion was decreased by MTX in U937 but not JKT cell lines (top left). Decreased viability of U937 cells increased over time of incubation with
MTX (1 uM) but not with HCQ (1 uM; top right). Forward/side scatter plots show changes consistent with decreased viability of U937 cells after
72 hours of culture with MTX (1 uM) but not with HCQ (1 uM; lower left). Apoptosis measured by 7-AAD was increased in dose- and time-
dependent fashion by MTX but was not induced by HCQ (lower right). P values were determined by one-way ANOVA. 7-AAD, 7-amino
actinomycin D; ANOVA, analysis of variance; HCQ, hydroxychloroquine; LPS, lipopolysaccharide; MTX, methotrexate.
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had no significant effect. A greater than 40% decrease in
viable U937 cells in 48 and 72 hour MTX (1 uM) cultures
was also measured using the MTT assay (P <0.002). Flow
cytometry profiles confirmed the presence of fewer viable
cells in the forward scatter/side scatter (FSC/SSC) win-
dow for the cultures with added MTX, but not with HCQ
(Figure 1). MTX mediated a dose- and time-dependent in-
crease in apoptosis of U937 cells as measured by 7-AAD
(Figure 1); HCQ did not show an effect on the apoptosis
profile.
Cytokine expression
Secretion of both IL-1 and IL-6 into culture supernatants
was increased by MTX in a dose-dependent fashion
(Figure 2, top panels). The increases were significantly dif-
ferent from the control baseline at a MTX concentration
of 1.0 uM. Expression levels of associated gene specificities
for IL-1 and IL-6, normalized to GAPDH expression, were
also significantly elevated in MTX cultures at the highest
concentration tested, 1.0 uM (Figure 2 bottom panels).
Levels of secreted TNF-alpha were also increased in 72
hour cultures from 13 pg/mL in control cultures to 408 pg/
mL in MTX (1 uM) cultures (P = 0.022; not shown in
figures).
Mechanisms of cytokine induction
The role of NF-kB signaling in the effects of MTX on
cytokine induction was investigated by adding the inhibi-
tor PAR. Direct addition of PAR (1 ug/ml) to U937 cellshad no effect on U937 viability, which was greater than
90% after 72 hours of culture. Co-culture of PAR with
MTX resulted in significant decreases in IL-1 and IL-6
gene expression to levels that were not significantly dif-
ferent than control cultures (Figure 3, top panels). In
addition, secreted levels of IL-1 and IL-6 were signifi-
cantly decreased with addition of PAR to the MTX cul-
tures (Figure 3 bottom panels). These results suggest
that the MTX-induced upregulation of IL-1 and IL-6 is
dependent on NF-kB.
Possible involvement of the adenosine pathway on these
cytokine effects was probed by culturing U937 cells with
THEO and CAFF [19]. These two drugs when added in-
dividually (1 uM) had no effect on cell viability. When
present in culture in combination with MTX, no signifi-
cant change in IL-1beta or IL-6 gene expression was ob-
served (Figure 4, top panels), suggesting that the adenosine
pathway was not responsible for the cytokine response. In
contrast, addition of folinic acid to MTX cultures resulted
in decreased IL-1beta and IL-6 gene expression (Figure 4,
bottom panels) suggesting a role for folate-dependent
pathways in mediating cytokine induction.
Effects on JUN pathway genes
In previous studies we have shown that levels of JNK1
and JNK2 are decreased in lymphocytes from patients
with RA, and that MTX treatment results in increased
levels of these signaling molecules along with a decrease
in sensitivity of lymphocytes to apoptotic signals [10].
To evaluate the role of these pathways in the observed



















































Figure 2 Production of IL-1 and IL-6 measured by ELISA in supernatants of U937 cells after 72 hours of culture with MTX showed
dose-dependent increases (top panels). Similar increases in corresponding gene expression levels for IL-1 and Il-6, expressed as Delta Ct values,
also were measured (bottom panels). P values were determined by one-way ANOVA and post hoc analyses confirmed significant (P <0.05)
increases at MTX 1.0 uM (indicated by asterisks) compared to cultures with no added MTX for all four measures. ANOVA, analysis of variance;
ELISA, enzyme-linked immunosorbent assay; IL, interleukin; MTX, methotrexate.
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cultured cells, and found that JUN and FOS, but not
JNK 1 or JNK 2, were upregulated by MTX, but not by
HCQ, in a time- and dose-dependent manner (Figure 5).
Addition of PAR to these MTX cultures did not signifi-
cantly decrease the levels of FOS and JUN (data not
shown). Expression levels of JUN and FOS were each
correlated with levels of IL-1beta gene expression (R2
values of 0.86 and 0.97, respectively).
Discussion
The findings reported here demonstrate proinflammatory
effects of MTX on human monocyte/macrophage cells in-
cluding gene upregulation and secretion of the cytokines
IL-1, IL-6 and TNF-alpha. The underlying mechanism ap-
pears to be consistent with an action on the NF-kB path-
way rather than through adenosine receptors. Doses of
MTX used in these studies are in a range that would be
achievable with in vivo treatment of malignancies or auto-
immune disease. So even though these are in vitro studies
on a cell line, the results may have implications for actions
of MTX in treated patients. Although no effects were ob-
served on human peripheral blood cells (data not shown),
localized tissue effects may contribute to some of the off-
target actions of this drug.These proinflammatory effects of MTX are of interest
because this drug is widely used to treat inflammatory and
autoimmune disorders including RA, psoriatic arthritis
and inflammatory myopathies. Mechanisms by which the
low-dose intermittent regimen has clinical effects in these
diseases remain somewhat obscure. The earliest concept,
borrowed from oncology applications, was that of anti-
proliferative actions, thereby reducing the burden of in-
flammatory cells [7]. Other potential mechanisms have
been proposed, including interactions with adenosine sig-
naling pathways and generation of ROS [8,19,20]. In previ-
ous studies we have shown that MTX primes T cells for
apoptosis, an action that is dependent on JNK signaling
pathways [16]. Overall, these effects likely result in a re-
duced inflammatory burden that translates into decreased
levels of damage in treated patients.
However, other effects of MTX that have been reported
appear to be directly contradictory to those that would be
desirable for treatment of inflammatory conditions like
RA. It is possible that these responses are relevant to some
of the toxic, or off-target, effects of MTX that include bone
loss, mucositis and pulmonary inflammation, especially at
the higher doses used in chemotherapeutic regimens. Con-
sistent with this is a short-term chemotherapy model in
which MTX treatment in rats resulted in activation of NF-
 IL-1 



















































Figure 3 IL-1 and IL-6 gene expression levels, normalized to GAPDH and expressed as Delta Ct values, were significantly increased by
addition of MTX (1 uM) to 72 hour cultures of U937 cells and these increases were blocked by co-culture of MTX with PAR (1 uM) to
levels that were not significantly different than those in control (CTRL) cultures (top two panels). P values for the gene expression
comparisons were calculated by one-way ANOVA, and Dunnett’s post test showed that only the MTX cultures were significantly different
(*P <0.05) from corresponding CTRL cultures. Furthermore, secreted IL-1 and IL-6 cytokines measured by ELISA in these 72 hour U937 supernatants
were significantly decreased when cells were co-cultured with MTX and PAR (bottom two panels). Significance (P values) for the IL-1 and IL-6
supernatants was calculated by paired t test. ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; MTX,
methotrexate; PAR, parthenolide.
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[15]. Other studies using MTX treatment in rats have
shown induction of TNF-alpha, IL-1beta and macrophage
inflammatory protein (MIP)-2 in the small intestine and
these inflammatory cytokines likely mediate mucositis in
the intestine and elsewhere in the gastrointestinal tract
[12,14]. Relevant to pulmonary toxicity is the finding MTX
has been shown to enhance expression of IL-1beta and Il-
8 in a human bronchial cell line via the p38 MAPK sig-
naling pathway [21]. Increased levels of these cytokines in
localized areas of bone might explain why high doses of
MTX have been associated with bone loss in oncology
patients, although this has been rarely reported in pa-
tients treated with low-dose regimens for diseases like
RA [22,23].
Although it might be anticipated or assumed that
MTX would have negative regulatory effects on cytokine
production, this in fact has not been clearly demon-
strated in experimental models or in treated patients. An
older investigation carried out prior to the availability of
immunoassays failed to show inhibition of IL-1 secre-
tion, although functional activity of the cytokine was re-
duced [24]. It has been suggested that levels of IL-1 in
the joint space of patients treated with MTX may be de-
creased due to changes in local production or compositionof synovial cell populations; but changes in peripheral
blood were not shown [25]. Investigations into effects of
MTX on IL-6 have had similar mixed results. In the murine
glucose-6-phosphate isomerase-induced arthritis model, for
example, treatment with MTX does not result in decreases
in either IL-6 or TNF alpha [26]. In a study of osteoblasts,
MTX alone had no effect on IL-6 synthesis, but it was able
to mediate decreased IL-6 production by these cells in re-
sponse to other inflammatory mediators [27]. This result
suggests that the existing inflammatory milieu may impact
cellular responses to MTX. Other findings suggest that the
anti-inflammatory cytokine IL-10 may be induced along
with proinflammatory mediators, and perhaps the relative
balance varies to impact the ultimate physiological ef-
fect [13].
A limitation of our studies is that they were carried out
in a cell line, and we did not observe stimulation of cyto-
kine production in human peripheral blood mononuclear
cells cultured with MTX (data not shown). However,
monocyte lineage cells are only a small component of
peripheral blood, and it is possible that effects of MTX
on minor cell types, perhaps even subsets of circulating
monocytes, are not sufficient to be measured in mixed cell
populations. The concept that at least some cell types re-















































































Figure 4 IL-1 and IL-6 gene expression levels, normalized to GAPDH and expressed as Delta Ct values, were increased with MTX and
not affected by addition of either CAFF or THEO (1 uM each). Addition of CAFF and THEO along with MTX (MCT) did not block the
stimulatory effects of MTX on IL-1 expression (top left). Significant differences for IL-1 gene expression were detected by one-way ANOVA
(P = 0.0061) followed by Dunnett’s multiple comparisons test, comparing each condition to control (CTRL). Only MTX and MCT cultures (indicated
by asterisks) were significantly different from CTRL (P <0.05). A similar pattern was observed for IL-6 expression (top right). Although the ANOVA
result was not statistically significant, only MTX and MCT cultures had any detectable IL-6 expression. Co-culture of MTX with FA (1 uM) blocked
significantly the normalized expression of IL-1 (bottom left), as shown by ANOVA (P = 0.0010) and in post hoc analyses only the MTX culture was
significantly different from CTRL (*P <0.05). A similar pattern was observed in a single experiment for IL-6 expression (bottom right). ANOVA,












































































































Figure 5 Normalized gene expression (Delta Ct) values for JUN and FOS in U937 cells were increased with MTX (1 uM) but not with
HCQ (1 uM). The increases in JUN and FOS observed with added MTX were time- and dose-dependent (right two panels). Values represent mean
and SEM; P values calculated using one-way ANOVA. ANOVA, analysis of variance; HCQ, hydroxychloroquine; MTX, methotrexate.
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ment. It is possible that specialized monocyte/macro-
phages in tissue locations such as bone or mucosa might
be more likely to generate inflammatory responses than
cells in the circulation. Some manifestations in treated pa-
tients, including mucositis, are often tempered or blocked
by the addition of folic acid supplements, which is consist-
ent with the observed reversibility of the cytokine re-
sponse with folinic acid. It is also possible that this is a
dose-related effect of MTX and that the higher doses used
in chemotherapeutic regimens are more likely to stimulate
inflammatory pathways.
Another implication of the current findings is that if
MTX stimulates production of even low levels of proin-
flammatory cytokines, this may be a reason why combining
MTX treatment with cytokine blocker drugs is efficacious
and has longer duration of drug survival than monotherapy
treatments, at least in some patients [5,28]. Further studies
to identify patients in whom this effect is significant could
be useful to predict those who are more likely to benefit
from addition of anti-cytokine agents to MTX.
Conclusions
MTX upregulates in the monocyte cell line U937 the pro-
duction of the proinflammatory cytokines IL-1, IL-6 and
TNF alpha. The folate pathway is implicated in this re-
sponse, while the adenosine signaling pathway is probably
not involved. These results may have implications for
explaining mechanisms of some off-target actions of MTX
such as mucositis and pneumonitis as well as decreased
bone density in oncology patients. Identification of pa-
tients in whom this response is significant might be useful
in predicting the need for combination therapy with anti-
cytokine agents.
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